Article
Gastroenterology & Hepatology
Heinz Zoller, Myles Wolf, Irina Blumenstein, Christian Primas, Stefan Lindgren, Lars L. Thomsen, Walter Reinisch, Tariq Iqbal
Summary: Despite comparable treatment efficacy for iron deficiency anaemia, FCM was associated with a higher incidence of hypophosphataemia compared to FDI. Further studies are needed to investigate the long-term clinical consequences of hypophosphataemia and the mechanisms underlying the differential effects of FCM and FDI on patient-reported fatigue.
Article
Hematology
Angelo Zullo, Vincenzo De Francesco, Luigi Gatta, Giuseppe Scaccianoce, Matteo Colombo, Roberto Bringiotti, Alessandro Azzarone, Angela Rago, Federico Corti, Alessandro Repici, Cesare Hassan, Roberta Elisa Rossi
Summary: Videocapsule Endoscopy (VCE) can be useful in identifying lesions on the small bowel mucosa in patients with iron deficiency anaemia (IDA), even when other endoscopies are negative. Non-steroidal anti-inflammatory drugs were found to be associated with these lesions.
ANNALS OF HEMATOLOGY
(2023)
Article
Nutrition & Dietetics
Malaine Morais Alves Machado, Mirella de Paiva Lopes, Raquel Machado Schincaglia, Paulo Sergio Sucasas da Costa, Alexandre Siqueira Guedes Coelho, Maria Claret Costa Monteiro Hadler
Summary: Fortification with multiple micronutrient powder was effective in preventing and treating iron deficiency and anemia in children aged six to 48 months. Additional supplementation of ferrous sulfate was necessary for anemic children.
Article
Nutrition & Dietetics
Evasio Pasini, Giovanni Corsetti, Claudia Romano, Roberto Aquilani, Tiziano Scarabelli, Carol Chen-Scarabelli, Francesco S. Dioguardi
Summary: This article discusses the blood-related issues caused by chronic diseases and treatment strategies for anemia. Emphasis is placed on the need for not only iron supplementation, but also providing all precursor molecules necessary for heme synthesis. Research shows that in elderly anemic patients, implementing personalized treatment strategies including supplementation of essential amino acids and vitamins can lead to a faster increase in hemoglobin levels.
Article
Medicine, General & Internal
Jose Maria Huguet, Xavier Cortes, Marta Maia Bosca-Watts, Margarita Munoz, Nuria Maroto, Marisa Iborra, Esther Hinojosa, Maria Capilla, Carmina Asencio, Cirilo Amoros, Jose Maria Paredes
Summary: A single 500 mg dose of intravenous ferric carboxymaltose (FCM) significantly increased iron parameters in patients with inflammatory bowel disease (IBD) and iron deficiency (ID), reduced ID symptoms, and significantly improved health-related quality of life (HRQoL) at 1 month after treatment.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Nutrition & Dietetics
Dagmara Mahadea, Ewelina Adamczewska, Alicja Ewa Ratajczak, Anna Maria Rychter, Agnieszka Zawada, Piotr Eder, Agnieszka Dobrowolska, Iwona Krela-Kazmierczak
Summary: Inflammatory bowel disease (IBD) often causes iron deficiency anemia, which significantly impacts quality of life and presents with various symptoms. Treatment should follow guidelines for monitoring anemia, considering appropriate therapy and the type of iron supplementation.
Article
Gastroenterology & Hepatology
Jonathon Snook, Neeraj Bhala, Ian L. P. Beales, David Cannings, Chris Kightley, Robert Ph Logan, D. Mark Pritchard, Reena Sidhu, Sue Surgenor, Wayne Thomas, Ajay M. Verma, Andrew F. Goddard
Summary: Iron deficiency anaemia is a major global cause of disease burden, diagnosed through blood testing and treated with iron replacement therapy. Causes include poor diet and gastrointestinal pathologies, with endoscopy and radiological scanning used for diagnosis and assessment in some cases.
Review
Medicine, General & Internal
Morris Gordon, Vassiliki Sinopoulou, Zipporah Iheozor-Ejiofor, Tariq Iqbal, Patrick Allen, Sami Hoque, Jaina Engineer, Anthony K. Akobeng
Summary: Inflammatory bowel disease affects approximately seven million people globally, with up to 90% of patients experiencing iron deficiency anaemia. The optimal treatment for this common systemic manifestation remains unclear among physicians. Studies evaluating the efficacy and safety of different interventions have yielded conflicting results, indicating the need for further research in this area.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Review
Medicine, General & Internal
Tamas Resal, Klaudia Farkas, Tamas Molnar
Summary: Iron deficiency anemia is a common extraintestinal manifestation of inflammatory bowel disease, significantly impacting patients' quality of life and mortality rate. Effective treatment requires addressing underlying pathological changes, and both oral and intravenous iron should be used more frequently.
FRONTIERS IN MEDICINE
(2021)
Article
Medicine, General & Internal
Roberta Loveikyte, Menno Boer, Catharina N. van der Meulen, Rinze W. F. ter Steege, Greetje Tack, Johan Kuyvenhoven, Bindia Jharap, My K. Vu, Lauran Vogelaar, Rachel L. West, Sander van der Marel, Tessa E. H. Romkens, Zlatan Mujagic, Frank Hoentjen, Adriaan A. van Bodegraven, Fiona D. M. van Schaik, Annemarie C. de Vries, Gerard Dijkstra, Andrea E. Van der Meulen-de Jong
Summary: This study assessed the prevalence of iron deficiency (ID) and anemia in Dutch outpatients with Inflammatory Bowel Disease (IBD) and compared the routine ID(A) management among medical professionals to the treatment guidelines. The findings showed that one in five IBD patients suffered from anemia, and most medical professionals treated anemic ID with standard doses of oral or intravenous iron while non-anemic ID was often overlooked.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Immunology
Yoji Sasahara, Takashi Uchida, Tasuku Suzuki, Daiki Abukawa
Summary: This review investigates the prevalence, clinical manifestation, genetic profile, and treatment of patients with early-onset inflammatory bowel disease (IBD) in Southeast and East Asia, specifically looking at the association with primary immunodeficiency diseases (PIDs). The study found that the prevalence of PID associated with IBD was higher in Southeast and East Asia compared to Western countries, and patients with bloody stools as an early symptom were more likely to have monogenic diseases. Comprehensive molecular diagnosis has been widely applied in this region to screen for PID-associated IBD patients. These findings contribute to the understanding of monogenic PIDs in early-onset IBD patients and their clinical manifestations and genetic profiles compared to Western countries.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Nutrition & Dietetics
Guillermo Bastida, Claudia Herrera-de Guise, Alicia Algaba, Yolanda Ber Nieto, Jose Manuel Soares, Virginia Robles, Fernando Bermejo, Esteban Saez-Gonzalez, Fernando Gomollon, Pilar Nos
Summary: This study showed that sucrosomial iron (SI) treatment is effective and well-tolerated for patients with iron deficiency anemia (IDA) and inflammatory bowel disease (IBD) who are intolerant to oral iron salts. It significantly increased hemoglobin levels and improved quality of life for patients.
Article
Gastroenterology & Hepatology
Roberta Loveikyte, Arno R. Bourgonje, Johannes J. van der Reijden, Marian L. C. Bulthuis, Lukas J. A. C. Hawinkels, Marijn C. Visschedijk, Eleonora A. M. Festen, Hendrik M. van Dullemen, Rinse K. Weersma, Harry van Goor, Andrea E. van der Meulen-de Jong, Gerard Dijkstra
Summary: Absolute iron deficiency is the main factor determining hepcidin levels, even in an inflammatory state. Induction therapy can decrease hepcidin levels, which may improve the availability of iron. Therefore, hepcidin is a potential diagnostic biomarker for iron deficiency and can assist in therapeutic decision making.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Biochemistry & Molecular Biology
R. Loveikyte, A. R. Bourgonje, H. van Goor, G. Dijkstra, A. E. van der Meulen-de Jong
Summary: This article discusses the effects of anemia and iron deficiency on patients with Inflammatory Bowel Disease (IBD), emphasizing the importance of treatment. Current data are limited and inconsistent, and further research is necessary to determine the impact of anemia and iron therapy on the redox status and intestinal microbiota.
Article
Gastroenterology & Hepatology
Jassin Rashidi-Alavijeh, Nargiz Nuruzade, Alexandra Frey, Eva-Maria Huessler, Anne Hoerster, Amos Cornelius Zeller, Andreas Schuette, Hartmut Schmidt, Katharina Willuweit, Christian Markus Lange
Summary: This study aimed to evaluate the role of iron supplementation in improving the prognosis of patients with cirrhosis. The results showed that an increase in hemoglobin levels was associated with improved transplant-free survival in patients with cirrhosis. The combination of iron supplementation and rifaximin had a stronger effect on prognosis.
Article
Gastroenterology & Hepatology
William J. Sandborn, Julian Panes, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt, Christopher Eden, Marco Daperno, John F. Valentine, David Laharie, Carolina Baia, Raja Atreya, Remo Panaccione, Grazyna Rydzewska, Humberto Aguilar, Severine Vermeire
Summary: This study compared the safety and efficacy of two doses of Etrolizumab with placebo in patients with Crohn's disease. The results showed that during the maintenance phase, Etrolizumab significantly improved clinical remission and endoscopic improvement in patients with moderately to severely active Crohn's disease compared to placebo. However, there was no significant difference in the effects of Etrolizumab and placebo on clinical remission and endoscopic improvement during the induction phase.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Javier P. Gisbert, Maria Chaparro
Summary: Infants exposed to biological drugs in utero have adequate serological responses to vaccines, and there are no relevant adverse events for non-live inactivated vaccines. Live-attenuated vaccines should be avoided in children with detectable levels of biological drugs. Breastfeeding by mothers treated with biologics is considered safe for infants, and the benefits of breastfeeding while receiving treatment and adhering to infant immunization programs outweigh any potential risk.
JOURNAL OF CROHNS & COLITIS
(2023)
Letter
Gastroenterology & Hepatology
Leire Leache, Marta Gutierrez-Valencia, Luis Carlos Saiz, Juan Uriz, Federico Bolado, Jose Antonio Garcia-Erce, Lorenzo Cantarelli, Juan Erviti
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Biotechnology & Applied Microbiology
Bernd Bokemeyer, Tibor Hlavaty, Matthieu Allez, Pamela Selema, Shahrzad Moosavi, Mary Jane Cadatal, Heather Fowler, Markus Mueller, Katherine F. Liau, Javier P. Gisbert
Summary: This study investigated the use of CT-P13 in the treatment of patients with Crohn's disease and ulcerative colitis. The results showed that the safety information for CT-P13 was consistent with the known safety profile for IFX and did not alter the established benefit-risk profile of CT-P13.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Gastroenterology & Hepatology
Julian Panes, Severine R. Vermeire, Geert D'Haens, Silvio Danese, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana R. Bravata, Daniel Gaya, Laurent Peyrin-Biroulet, Axel Dignass
Summary: This study compared two treatment strategies for Crohn's disease patients and found that regardless of whether the treatment was "treat-to-target" or "standard of care", ustekinumab was effective in improving the health-related quality of life and work productivity of patients over a 2-year follow-up period.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Article
Gastroenterology & Hepatology
Johan Burisch, Mirabella Zhao, Selwyn Odes, Peter De Cruz, Severine Vermeire, Charles N. Bernstein, Gilaad G. Kaplan, Dana Duricova, Dan Greenberg, Hans O. Melberg, Mamoru Watanabe, Hyeong Sik Ahn, Laura Targownik, Valerie E. H. Pittet, Vito Annese, K. T. Park, Konstantinos H. Katsanos, Marte L. Hoivik, Zeljko Krznaric, Maria Chaparro, Edward V. Loftus, Peter L. Lakatos, Javier P. Gisbert, Willem Bemelman, Bjorn Moum, Richard B. Gearry, Michael D. Kappelman, Ailsa Hart, Marieke J. Pierik, Jane M. Andrews, Siew C. Ng, Renata D'Inca, Pia Munkholm
Summary: The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide due to the steady increase in prevalence, the chronic nature of the diseases, expensive treatments, intensive monitoring, and their impact on productivity. This Commission urges evaluation of cost increases against improved disease management and the need for data interoperability and big data approaches to assess effectiveness and cost-effectiveness. International collaborations and novel care models should be sought to enhance education and training for clinicians, patients, and policy makers.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Javier P. Gisbert, Maria Chaparro
Summary: Surgery is not a cure for Crohn's disease, and postoperative recurrence is common. This article critically reviews the role of anti-TNF agents and new biologics in preventing and treating postoperative recurrence in Crohn's disease. Anti-TNFs have been shown to be the most effective agents in preventing and treating postoperative recurrence, while the effectiveness of vedolizumab and ustekinumab is still unclear.
Article
Gastroenterology & Hepatology
Angeles Perez-Aisa, Olga P. Nyssen, Alma Keco-Huerga, Luis Rodrigo, Alfredo J. Lucendo, Blas J. Gomez-Rodriguez, Juan Ortuno, Monica Perona, Jose Maria Huguet, Oscar Nunez, Luis Fernandez-Bermejo, Jesus Barrio, Angel Lanas, Eduardo Iyo, Pilar Mata Romero, Miguel Fernandez-Bermej, Barbara Gomez, Ana Garre, Judith Gomez-Camarero, Luis Javier Lamuela, Ana Campillo, Luisa de la Pena-Negro, Manuel Dominguez Cajal, Luis Bujanda, Diego Burgos-Santamaria, Fernando Bermejo, Victor Gonzalez-Carrera, Ramon Pajares, Pedro Almela Notari, Javier Tejedor-Tejada, Montserrat Planella, Itxaso Jimenez, Yolanda Arguedas Lazaro, Antonio Cuadrado-Lavin, Isabel Perez-Martinez, Edurne Amorena, Jesus M. Gonzalez-Santiago, Teresa Angueira, Virginia Flores, Samuel J. Martinez-Dominguez, Manuel Pabon-Carrasco, Benito Velayos, Alicia Algaba, Consuelo Ramirez, Enrique Alfaro Almajano, Manuel Castro-Fernandez, Noelia Alcaide, Patricia Sanz Segura, Anna Cano-Catala, Natalia Garcia-Morales, Leticia Moreira, Francis Megraud, Colm O'Morain, Xavier Calvet, Javier P. Gisbert
Summary: This study analyzed the effectiveness and safety of triple-dose administration of single capsule bismuth quadruple therapy (scBQT) in patients included in the European Registry on Helicobacter pylori Management. The results showed that the three times a day treatment schedule was more effective than the traditional four times a day schedule in terms of overall cure rates. There were no differences observed in treatment adherence or safety between the two regimens.
Meeting Abstract
Gastroenterology & Hepatology
M. Baldan-Martin, M. Azkargorta, I. Lloro, I. Soleto Fernandez, M. Orejudo, C. Ramirez, S. Garcia, J. Mercado, S. Riestra, M. Rivero, A. Gutierrez, I. Rodriguez-Lago, L. Fernandez-Salazar, D. Ceballos, J. M. Benitez, M. Aguas, I. Baston-Rey, F. Bermejo, M. J. Casanova, R. Lorente, Y. Ber, V. Royo, M. Esteve, F. Elortza, J. P. Gisbert, M. Chaparro
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. Baldan-Martin, I. Lloro, M. Azkargorta, C. Ramirez, I. Soleto Fernandez, M. Orejudo, S. Garcia, J. Mercado, C. H. Gordillo, S. Riestra, M. Rivero, A. Gutierrez, I. Rodriguez-Lago, L. Fernandez-Salazar, D. Ceballos, J. M. Benitez, M. Aguas, I. Baston-Rey, F. Bermejo, M. J. Casanova, R. Lorente, Y. Ber, V. Royo, M. Esteve, F. Elortza, J. P. Gisbert, M. Chaparro
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Guerra Marina, F. Barros, M. Chaparro, J. M. Benitez, M. D. Martin Arranz, R. de Francisco, M. Piqueras, L. de Castro, A. Y. Carbajo, F. Bermejo, M. Minguez, A. Gutierrez, F. Mesonero, F. Canete, C. Gonzalez-Munoza, M. Calvo, B. Sicilia, E. Alfambra, C. A. Tardillo, M. Rivero, A. J. Lucendo, L. Bujanda, M. Van Domselaar, P. Almela, L. Ramos, M. Fernandez Sanchez, E. Hinojosa, C. Verdejo, A. Gimenez, I. Rodriguez-Lago, N. Mancenido, J. L. Perez Calle, M. D. P. Moreno, P. G. Delgado-Guillena, B. Antolin, P. Ramirez de la Piscina, M. J. Casanova, A. Carracedo, E. Domenech, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
A. B. Julian, D. Casas-Deza, R. Vicente-Lidon, B. Beltran, E. Domenech, A. Gutierrez-Casbas, M. Manosa, Y. Zabana, E. Caudevilla-Biota, P. Corsino-Roche, E. Sierra-Moros, L. E. Franco-Fobe, S. Pina-Echevarria, E. Garcia-Gonzalez, E. Alfambra, C. Gargallo-Pueyo, B. Sicilia, L. Arias, M. J. Alcala-Escriche, L. Madero-Velazquez, R. Ferreiro-Iglesias, A. Palmero-Perez, M. Calafat, S. Rubio-Iturria, I. Moraleja-Yudego, Y. Ber-Nieto, S. Garcia-Mateo, J. P. Gisbert, M. Barreiro-de Acosta, S. Garcia-Lopez
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Guerra Marina, L. Bujanda, M. Manosa, I. Perez-Martinez, M. J. Casanova, L. de la Pena, M. de Benito, M. Rivero, P. Varela, L. Bernal, A. C. Franco, Y. Ber, M. Piqueras, C. Tardillo, A. Ponferrada, S. Olivares, A. J. Lucendo, P. Gilabert, M. Sierra Ausin, M. Bellart, A. Herrarte, M. Calafat, R. de Francisco, J. P. Gisbert, J. Guardiola, E. Domenech, F. Bermejo
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
J. F. Munoz Nunez, C. Rodriguez, J. P. Gisbert, S. Bernardo, J. Aparicio, I. Tagarro, F. Casellas
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Hematology
Eloisa Urrechaga, Monica Fernandez, Manuel Quintana, Jose Antonio Garcia Erce
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
